Business Context and Reporting Period
This Form 8-K Current Report from SANUWAVE Health, Inc. covers events occurring on January 31, 2020, with the report dated February 6, 2020. The filing details the entry into a definitive material agreement for a private placement of equity securities and the corresponding amendment to the Company's Articles of Incorporation.
Key Financial Metrics and Transaction Details
- Capital Raised: $2,250,000 aggregate purchase price.
- Instrument: 90 shares of Series C Convertible Preferred Stock.
- Stated Value: $25,000 per share.
- Conversion Price: $0.14 per share of Common Stock.
- Potential Dilution: Up to 16,071,428 shares of Common Stock upon full conversion.
- Investor Type: Accredited investors only.
Material Changes and Corporate Actions
The Company filed a Certificate of Designation with the Nevada Secretary of State on January 31, 2020, creating the new Series C Preferred Stock. The private placement closed on February 6, 2020. A critical material change is that the Series C Preferred Stock is not currently convertible because the Company lacks sufficient authorized and unissued Common Stock to permit full conversion.
Outlook, Risks, and Contingencies
- Authorization Requirement: The Company must amend its Articles of Incorporation to increase authorized Common Stock to enable conversion. Investors have agreed to convert their shares within five business days of such an amendment.
- Redemption Contingency (Authorization Failure): If shareholder approval to increase authorized shares is not obtained or filed by December 31, 2020, the Company must redeem all outstanding Series C Preferred Stock.
- Redemption Price: Payable in cash within 30 days of the failure date, equal to the greater of:
- 200% of the stated value ($50,000 per share); or
- The market value of the underlying Common Stock shares (based on a 30-day VWAP) multiplied by the conversion ratio.
- Liquidity Risk: The potential redemption obligation could require a significant cash outlay if the Company fails to secure the necessary capitalization increase by the deadline.
Investor Verification Checklist
- Verify the Company's current authorized share count and the status of any pending amendments to increase authorized Common Stock.
- Confirm the Company's current cash position and liquidity to assess its ability to meet the potential redemption obligation (up to $4.5 million or more) if the December 31, 2020, deadline is missed.
- Review the full text of the Certificate of Designation (Exhibit 3.1) and Purchase Agreement (Exhibit 10.1) for specific adjustment mechanisms and covenants.
- Monitor shareholder meeting schedules to determine if a vote on increasing authorized shares is planned before the 2020 deadline.